LenioBio GmbH today announced a strategic partnership with AffinityAI, a Danish start-up pioneering AI-driven protein design. This collaboration combines LenioBio’s proprietary cell-free protein expression platform, ALiCE®, with AffinityAI’s advanced design engine, Designerbodies, to significantly accelerate the discovery and optimization de novo proteins. By integrating AI-guided protein design with high-throughput cell-free expression, the partnership closes the traditional “lab-in-loop” gap,










